Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention.

Biochimica et biophysica acta - 1 Jan 2000

Groener J E M, Poorthuis B J H M, Kuiper S, Hollak C E M, Aerts J M F G

Abstract excerpt

The concentrations of plasma glucosylceramide (GlcCer) and ceramide (Cer) were determined in a cohort of type 1 Gaucher disease patients. In plasma of untreated patients, GlcCer concentrations were on average 3-fold increased (median Gaucher: 17.5 nmol/ml, range: 6.5-45.5 (n=27); median control: 5.9 nmol/ml, range 4.0-8.6 (n=15)). Although plasma Cer concentrations were not significantly different between the two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Biomarkers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Ceramides

Share to Gaucher Disease

Share to Glucose

Share to Lipid Metabolism

Share to Phenotype

Source

Identifiers

PMID: 18155675
DOI: 10.1016/j.bbalip.2007.11.004

Genes

CCL18

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention.PMID 18155675Read ↗

Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - A statistical insight.Semantic proximity Read ↗

Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease PatientsSemantic proximity Read ↗

Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.Semantic proximity Read ↗

Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease.Semantic proximity Read ↗

LC-MS/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population.Semantic proximity Read ↗

Emerging therapeutic targets for Gaucher disease.Semantic proximity Read ↗

Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity.Semantic proximity Read ↗

Therapeutic goals in Gaucher disease.Semantic proximity Read ↗

CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings.Semantic proximity Read ↗

Gaucher disease: a heterogeneous clinical complex for which effective enzyme replacement has come of age.Semantic proximity Read ↗

The Importance of a Multidisciplinary Approach in the Management of a Patient with Type I Gaucher DiseaseSemantic proximity Read ↗

[Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.